| Ytd | -71.24% | |
| 1y | -49.06% |
| Open | 5.03 | Prev Close | 5.04 | Low | 4.84 | High | 5.07 | Mkt Cap | 964.55M |
| Vol | 2.32M | Avg Vol | 3.08M | EPS | -1.08 | P/E | N/A | Forward P/E | -4.33 |
| Beta | -1.26 | Short Ratio | 5.75 | Inst. Own | 85.60% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-09 | 50-d Avg | 5.74 | 200-d Avg | 9.36 | 1yr Est | 19.06 |
WVE News
Wave Life Sciences (NASDAQ:WVE) trades at $5.24, a step above its 52-week low of $5.01 and far benea
Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript
CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (NASDAQ: WVE), a clinic
CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd.
Mizuho analyst Salim Syed maintains WAVE Life Sciences (NASDAQ:WVE) with a Outperform and lowers
CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinica
Citigroup analyst Samantha Semenkow maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and lowe
B. Riley Securities analyst Madison El-Saadi maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy
Wedbush analyst Yun Zhong maintains WAVE Life Sciences (NASDAQ:WVE) with a Outperform and lowers
WAVE Life Sciences NASDAQ: WVE reported a wider second-quarter loss as it increased investment in it
Wave Life Sciences Ltd. (WVE) Q2 2026 Earnings Call Transcript
Wave Life Sciences (WVE) came out with a quarterly loss of $0.34 per share versus the Zacks Consensu
WAVE Life Sciences (NASDAQ:WVE) reported quarterly losses of $(0.34) per share which missed the anal
Dosing underway in Phase 2a multidose portion of the INLIGHT TM trial of WVE-007 (INHBE GalNAc-siRN
CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinica
Wave Life Sciences (WVE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optim
HTLD, YEXT, ANIX, WVE and LCNB have been added to the Zacks Rank #1 (Strong Buy) List on July 22, 20
Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid a
CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd.
The consensus price target hints at a 294.7% upside potential for Wave Life Sciences (WVE). While em
In Phase 1 portion of trial, WVE-007 improved body composition by inducing fat loss, including harmf
In Phase 1 portion of trial, WVE-007 improved body composition by inducing fat loss, including harmf
Wave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which i
Wave Life Sciences Ltd. (WVE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 202
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinica
This clinical-stage biotech develops precision genetic medicines for neurological and hepatic disord
Wells Fargo analyst Benjamin Burnett maintains WAVE Life Sciences (NASDAQ:WVE) with a Overweight
HC Wainwright & Co. analyst Andrew S. Fein maintains WAVE Life Sciences (NASDAQ:WVE) with a B
Data reinforce WVE-006's potential to address both lung and liver manifestations of AATD with a
Citigroup analyst Samantha Semenkow maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and lowe
Canaccord Genuity analyst Whitney Ijem maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and l
Truist Securities analyst Danielle Brill maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking t
Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking th
Top Wall Street analysts have changed their outlook on top names. For full analyst rating changes, i
HC Wainwright & Co. analyst Andrew S. Fein maintains WAVE Life Sciences (NASDAQ:WVE) with a B
US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen
B of A Securities analyst Alec Stranahan maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and
Wells Fargo analyst Benjamin Burnett maintains WAVE Life Sciences (NASDAQ:WVE) with a Overweight
The U.S. trade deficit in goods shrank to $87.3 billion in February from $88.6 billion in January, w
Wave Life Sciences stock drops after INLIGHT Phase 1 data. WVE-007 shows fat reduction, lean mass st
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking t
Mizuho analyst Salim Syed maintains WAVE Life Sciences (NASDAQ:WVE) with a Outperform and raises
Canaccord Genuity analyst Whitney Ijem maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and r
Wedbush analyst Yun Zhong maintains WAVE Life Sciences (NASDAQ:WVE) with a Outperform and raises
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking t